Elizabeth D. Bierbower
Elizabeth D. Bierbower's purchase track record
Elizabeth D. Bierbower has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/30/2023 | OPCH | $79K | +17.9% | +12.8% | +22.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
McKesson moves to acquire Option Care Health in $5.8B deal. Option Care Health is the target of a $5.8 billion acquisition by McKesson, which has lifted the stock in recent trading. The deal is under legal review, and several analysts have lowered their ratings, with UBS moving to neutral and William Blair to market‑perform. The mixed reactions reflect both the premium offered and the uncertainties around regulatory approval.
Transaction History
| PGNY | ▲ Buy | Grant | 5,660 | $0 | 5/21/2026 | View on chart |
| OPCH | ▲ Buy | Grant | 8,997 | $0 | 5/20/2026 | View on chart |
| OPCH | ▲ Buy | Grant | 5,034 | $0 | 5/14/2025 | View on chart |
| OPCH | ▲ Buy | Grant | 5,325 | $0 | 5/15/2024 | View on chart |
| OPCH | ▲ Buy | Open Market | 3,000 | $79K | 10/30/2023 | View on chart |
| OPCH | ▲ Buy | Grant | 5,322 | $0 | 5/17/2023 | View on chart |
| OPCH | ▲ Buy | Grant | 5,193 | $0 | 5/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Progyny (PGNY) shares rise over 6% amid record sales pace
Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.
Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.